Vivos Therapeutics Reports Widening Q1 Loss and Increased Cash Burn Amid Ongoing Nasdaq Delisting Risk

summarizeSummary

Vivos Therapeutics reported a significantly wider net loss and increased cash burn in Q1 2026, reiterating a 'going concern' warning and ongoing Nasdaq delisting risk despite recent equity raises.

check_boxKey Events

• Net Loss Widens Significantly

  Net loss for Q1 2026 more than doubled to $7.75 million, compared to $3.86 million in Q1 2025.

• Increased Cash Burn

  Net cash used in operating activities increased to $6.01 million in Q1 2026, up from $3.80 million in Q1 2025.

• Going Concern Warning Reiterated

  The company explicitly states its $2.11 million in cash and cash equivalents as of March 31, 2026, is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

• Ongoing Nasdaq Delisting Threat

  Vivos Therapeutics received a Nasdaq notice on April 17, 2026, for non-compliance with the minimum stockholders' equity requirement ($2.5 million), with a plan to regain compliance due by June 1, 2026.

auto_awesomeAnalysis

Vivos Therapeutics' Q1 2026 results highlight a critical financial situation, with net losses doubling and cash burn significantly increasing year-over-year. Despite a 70% revenue increase, the company explicitly states its cash is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. The company also faces an active Nasdaq delisting threat due to negative stockholders' equity, requiring a compliance plan by June 1, 2026. Recent equity financings provided temporary capital but did not resolve the underlying financial instability or Nasdaq deficiency.